AU7084787A - Eucaryotic expression of steroid receptor proteins - Google Patents
Eucaryotic expression of steroid receptor proteinsInfo
- Publication number
- AU7084787A AU7084787A AU70847/87A AU7084787A AU7084787A AU 7084787 A AU7084787 A AU 7084787A AU 70847/87 A AU70847/87 A AU 70847/87A AU 7084787 A AU7084787 A AU 7084787A AU 7084787 A AU7084787 A AU 7084787A
- Authority
- AU
- Australia
- Prior art keywords
- cells
- expression
- steroid
- sequences
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000014509 gene expression Effects 0.000 title claims description 40
- 102000005969 steroid hormone receptors Human genes 0.000 title claims description 23
- 108010085012 Steroid Receptors Proteins 0.000 title claims description 21
- 210000004027 cell Anatomy 0.000 claims description 40
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 102000015694 estrogen receptors Human genes 0.000 claims description 18
- 108010038795 estrogen receptors Proteins 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 150000003431 steroids Chemical class 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000006166 lysate Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 description 17
- 108020003175 receptors Proteins 0.000 description 17
- 239000002299 complementary DNA Substances 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 239000000556 agonist Substances 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 8
- 239000003623 enhancer Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 238000004062 sedimentation Methods 0.000 description 7
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 6
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 229960005309 estradiol Drugs 0.000 description 6
- 229930182833 estradiol Natural products 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- JDKLPDJLXHXHNV-MFVUMRCOSA-N (3s,6s,9r,12s,15s,23s)-15-[[(2s)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1h-imidazol-5-ylmethyl)-3-(1h-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxamide Chemical compound C([C@@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCNC(=O)C[C@@H](C(N[C@@H](CC=2NC=NC=2)C(=O)N1)=O)NC(=O)[C@@H](NC(C)=O)CCCC)C(N)=O)C1=CC=CC=C1 JDKLPDJLXHXHNV-MFVUMRCOSA-N 0.000 description 3
- 101710201349 Metallothionein B Proteins 0.000 description 3
- 101710094505 Metallothionein-2 Proteins 0.000 description 3
- 102100031347 Metallothionein-2 Human genes 0.000 description 3
- 102000043276 Oncogene Human genes 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 101001014059 Homo sapiens Metallothionein-2 Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000015393 sodium molybdate Nutrition 0.000 description 2
- 239000011684 sodium molybdate Substances 0.000 description 2
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 108020003113 steroid hormone receptors Proteins 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 1
- 101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000713842 Avian sarcoma virus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 101100440699 Drosophila melanogaster corto gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241001288713 Escherichia coli MC1061 Species 0.000 description 1
- 108010085330 Estradiol Receptors Proteins 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 101000926939 Homo sapiens Glucocorticoid receptor Proteins 0.000 description 1
- 101001071608 Homo sapiens Glutathione reductase, mitochondrial Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 150000002338 glycosides Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- -1 isocytochrome C Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 102000005963 steroid binding proteins Human genes 0.000 description 1
- 108020003178 steroid binding proteins Proteins 0.000 description 1
- 230000037359 steroid metabolism Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Description
EUCARYOTIC EXPRESSION OF STEROID RECEPTOR PROTEINS
Technical Field
The invention relates to production of desired proteins using recombinant technology, Specifically, it concerns production of steroid receptor proteins employing eucaryotic hosts and expression systems compatible with these hosts.
Background Art
Steroid hormone receptors are well known to regulate gene expression in eucaryotic cells. The action of steroid hormones in vertebrates involves interaction of the specific intracellular steroid receptor protein (SR) with the genome, and in addition, steroid hormones and SR proteins are involved in the regulation of tumor growth in many instances (Lippmann. M .E., Breast Cancer: Trends in Research and Treatment (Raven, NY 1975); Lippmann, M.E., et al, Nature (1975) 256 : 592). It is believed that binding of the steroid converts the SR protein to a form which binds strongly to nuclear DNA, although the nature of this interaction and the location of the binding is not understood. It is known that steroid receptor protein, specifically estrogen receptor (ER) is distributed in a tissue-specific manner and the expression of this protein is developmentally regulated. ER from several sources has been purified and shown to have a molecular weight of 65-70 kd (Redeuilh, C, et al Eur J Biocherm (1980) 106:481; Lubahn, D.B., et al, J Biol Chem (1985) 260:2215; Katzenellenbogon, B.S., et al, J Biol Chem (1983) 258:3487; Sakai, D., et al, Endocrinol (1984) 115:2379, van Oosboree, T R., et al, Anal Bio chem (1984)
136:321). In addition, related human gluto corto coid receptor (GR) cDNA has been prepared (Hollenberg, S.M., et al. Nature (1985) 318:635).
Recently, the cDNA encoding human estrogen receptor (hER) was isolated from randomly primed λgt10 and λgt11 cDNA libraries prepared from the human breast cancer cell line, MCF-7, and screened with monoclonal anti-ER antibodies and with synthetic oligonucleotides corresponding to two peptide sequences obtained from MCF-7 human ER. This work is reported in Walter, P., et al, Proc Natl Acad Sci (USA) (1985) 82:7889-7893, which is incorporated herein by reference. Among the cDNA clones isolated by oligonucleotide hybridization was a 2.1 kb cDNA clone designated OR8 which cross-hybridized with all other cDNAs and which contained the expected sequences for the two ER peptides. In addition, this cDNA hybridized selectively to a 6.2 kb poly-A RNA which, when translated in vitro in the presence of 35S-methionine, was shown to encode the synthesis of immunoreactive 65 kd hER as well as a smaller amount of immunoreactive 46 kd protein. The OR8 cDNA insert was long enough to contain the entire coding sequence for the 65 kd protein. In the invention herein, the OR8 cDNA clone was successfully incorporated into an expression system compatible with mammalian host cells, and recombinant hER produced using transformed mammalian cell cultures. The availability of expression systems for hER and other steroid receptor proteins provides the ability to produce large amounts of purified steroid receptor proteins, and their production in eucaryotic hosts assures that post-translational processing and folding which is capable of regenerating material closely
analogous to the natively produced intracellular protein will be obtained.
Disclosure of the Invention The invention provides the complete DNA sequence encoding human estrogen receptor protein (hER) along with the deduced amino acid sequence. The availability of this sequence information permits comparisons with related receptor proteins such as the glucocortocoid receptor and the v-erb-A (AEU) oncogene product.
In addition, the pertinent coding sequence has been incorporated into an expression system operable in eucaryotic host cells, and specifically mammalian host cells. This permits expression of the sequences under conditions which favor appropriate post-translational processing, and provides quantities of protein useful for design of agonist and antagonist compounds, for study of the mechanism of action of the steroid binding proteins in general, and for use in diagnostic assays for SR proteins themselves or for antibodies raised against them.
Thus, in one aspect, the invention relates to an expression system for a vertebrate steroid receptor protein which contains DNA encoding the receptor protein operably linked to control sequences capable of expressing these sequences in eucaryotic host cells. In additional aspects, the invention relates to recombinant host eucaryotic cells containing the expression system of the invention, to methods of producing steroid receptor proteins using these cells, and to these steroid receptor proteins so produced.
Brief Description of the Drawings
Figure. 1 shows the cDNA sequence encoding human estrogen receptor protein and the deduced amino acid sequence.
Figure 2 shows comparative amino acid sequences for hER, human GR, and a putative AEU oncogene protein.
Figure 3 shows sedimentation analysis of human estrogen receptor expressed by OR8 cDNA in CHO K-1 cells.
Modes of Carrying Out the Invention A. Definitions
"Expression system" refers to a collection of components as subsequently designated and may include, as specified, only a coding sequence, operably linked to control sequences, to these sequences further linked to an enhancer, to a vector containing these, and any further DNA sequence relevant to effecting expression. "Human metallothionein-II" promoter (hMT-II) refers to control sequences derived From the human MT-II gene or their functional equivalents. The control sequences of this gene are. described in detail by Karin, M., et al. Nature (1982) 299:797-802.
"Chinese Hamster Ovary" (CHO) cells include the standard cell line ATCC CCL-61, and its relatives isolated from the same source, tissue, as well as derivatives thereof. Derivatives are mutants of the line which may differ genotypically or phenotypically from the. original line, but which are obtained therefrom by intentional or inadvertent mutation.
"Derived from" as it pertains to, for example, DNA or protein sequences refers to similarity in structure and no. necessarily to physical derivation.
"Purified" or "pure" refers to material which is free from substances which normally accompany it as found in its native state. Thus "pure" SR, for example, refers to SR which does not contain materials normally associated with its in situ environment in human cells. Of course, "pure" SR may include materials in specific association with it, such as its glycoside residues. "Operably linked" refers to a juxtaposition wherein the components are configured so as to perform their usual function. Thus, control sequences or promoters operably linked to a coding sequence are capable of effecting the expression of the coding sequence.
"Control sequence" refers to a DNA sequence, or sequences which are capable, when properly ligated to a desired coding sequence, of effecting its expression in hosts compatible with such sequences. Such control sequences include, promoters and termination signals. Additional factors necessary or helpful in effecting expression such as enhancers may also be identified. As used herein, "control sequences" simply refers to whatever DNA sequence may be required to effect expression in the particular host used.
"Cells" or "cell cultures" or "recombinant host cells" or "host cells" are often used interchangeably as will be clear from the context. These terms include the immediate subject cell, and, of course, the progeny thereof. It is understood that not all progeny are exactly identical to the parental cell, due to chance mutations or differences in environment. However, such altered progeny are included in these terms, so long as the progeny retain the characteristics relevant to those conferred on the originally transformed cell.
B. General Description
The invention herein represents the first expression of a steroid receptor protein under environmental conditions which are conducive to mimicing the native product. To effect such expression, the cDNA, genomic DNA or other DNA encoding the desired vertebrate steroid receptor protein is placed under control of control sequences operable in eucaryotic cells for expression. The invention is illustrated below with respect to human estrogen receptor; however, it is recognized that using expression systems of the invention, including that specifically illustrated, other steroid receptors may be successfully produced.
In order to obtain a valid construction of the native, protein, it is desirable that the. production be effected in eucaryotic hosts. Common eucaryotic hosts include yeast and mammalian cells. A particular expression system for mammalian cells is illustrated below; however, alternate expression systems are also available and could be employed with suitable. modifications to obtain expression of appropriate steroid receptor encoding sequences.
Eucaryotic microbes, though less, desirable than mammalian cultures may be. used as hosts. Laboratory strains of Saccharomyces cerevisiae, Baker's yeast, are most used although a number of other yeast strains are commonly available. Vectors employing, for example, the 2 μ origin of replication of Broach, J. R., Meth Enz (1983) 101:307, or other yeast compatible origins of replications (see, for example, Stinchcomb, et al, Nature (1979) 282:39, Tschempe, et al, Gene (1980) 10:157 and Clarke, L, et al, Meth Enz (1983) 101:300) may be used. Control sequences for yeast vectors include promoters for the synthesis of glycoxytic
enzymes (Hess, et al, J Adv Enzyme Reg (1968) 7:149; Holland, et al, Biochemistry (1978) 17:4900). Additional promoters known in the art include the promoter for 3-ρhosphoglycerate kinase (Hitzernan, et al. J Biol Chem (1980) 255:2073), and those for other glycolytic enzymes. Other promoters, which have the additional advantage of transcription controlled by growth conditions are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, and enzymes responsible for maltose and galactose utilization. It is also believed terminator sequences are desirable at the 3' end of the coding sequences. Such terminators are found in the 3' untranslated region following the. coding sequences in yeast-derived genes. Transformations into yeast may be carried out according to the method of Uan Solingen, P., et al, J. Bact (1977) 110:946 or of Hsiao, C. L., et al, Proc NatlAcad Sci (USA) (1979) 76 : 3829. Mammalian host cell expression is, however preferred, and general techniques for such expression are known. See, for example, Axel, et al, 4,399,216. These systems have the. additional advantage of the ability to splice out introns and thus can be used directly to express genomic fragments. Useful host cell lines include VERO and HeLa cells, and Chinese hamster ovary (CHO) cells. Expression vectors for such cells ordinarily include promoters and control sequences compatible with mammalian cells such as, for example, the commonly used early and late promoters from Simian Virus 40 (SV 40) (Fiers, et al, Nature (1978) 273:113), or other viral promoters such as those derived from polyoma, Adenovirus 2, bovine papiloma virus, or avian sarcoma viruses. The controllable promoter, hMTII
(Karin, M., et al, Nature (1982) 299:797-802) may also be used. It now appears, also that "enhancer" regions are important in optimizing expression; these are, generally, sequences found upstream or downstream of the promoter region in non-coding DNA regions; these are also illustrated below. Origins of replication may be obtained, if needed, from viral sources. However, integration into the chromosome is a common mechanism for DNA replication in eucaryotes. For mammalian cells the calcium phosphate precipitation method of Graham and van der Eb, Virology (1978) 52:546, optionally as modified by Wigler, M., et al, Cell (1979) 16:777-785 may be used.
To effect the desired expression in eucaryotic hosts, the gene sequences are ligated into suitable control sequences transformed into the compatible host cells and the cell cultures grown under appropriate conditions. If the control sequences include inducible promoters, appropriate induction conditions are supplied. As the steroid receptor proteins are intracellular, they lack signal sequences and are normally preceded by a methionine start codon. Alternate constructions which delete this codon and include heterologous signal sequences capable of effecting the secretion of this protein from the host are also capable of construction. The signal sequences from, for example, normally secreted mammalian proteins such as renin, growth hormone, or insulin are known in the art and could be used. If for expression in yeast, yeast signal sequences such as those associated with α factor can be employed.
C . Utility
The availability of significant amounts of purified steroid receptor protein is advantageous in both diagnostic assays and in designing means for regulating steroid mediated metabolism. In connection with the former, it may be desirable to assess the levels of receptor present in various tissues as a diagnostic tool for disorders of steroid regulated metabolism, and also to assess the susceptibility of various tumors to control by regulation of steroid supply. In addition, it is possible to raise antibodies specific for steroid receptors, and the aυailability of large amounts of antigen facilitates the assays for them, Thus, the desirability of obtaining pure recombinant human estrogen receptor and other steroid hormone receptors has several facets. First, milligram amounts of the material are obtainable using this procedure. Milligram amounts are capable of crystallization to permit three dimensional studies using X-ray diffraction and computer analysis. This permits deductions concerning the shape of the molecule, thus defining proper shapes for substances useable as agonists and antagonists of the hormone. Agonists and antagonists are critically important in regulating those aspects of metabolism mediated by steroids, including reproductive function, inflammatory responses, blood pressure, and secondary sex characteristics. The responsiveness of some tumors to steroids is also known, and is reinforced by the disclosure herein of regional homology between human ER, glucocortocoid receptor, and a putative v-erb-A oncogene product.
ER and other steroid receptors have DNA and steroid binding domains, and agonists or antagonists to steroid activity are substances whose interactions with
SR are stabilized by design of the 3-dirnensional structures so as to enhance the ability of the substance, to interact positively and specifically with a particular region of the SR. This lock and key spatial arrangement will result from molecules designed, complementary to the surface contours of the crystallized ER or other steroid receptor of the invention. It is understood that "surface" includes convolutions which may face inward, and specifically includes both normal sites of interaction and internal structure which results in these sites. Furthermore, "complementary" is understood to mean that in addition to spatial conformations which "fit", interactions between the receptor and the molecule, which matches its surface contours are. attractive and positive. These interactions may be hydrogen bonding, ionic, or hydrophobic affinity. Antagonists and agonists are modified steroids complementary to the. 3-D structure.
Second, even without the assistance of a three dimensional structure determination, purified receptors of the invention are of significance, as reagents in screening agonists and antagonists in vitro as an ad hoc approach to evaluation. Impure receptor preparations currently available yield confusing data due to the impact of the impurities on the test results. For example, contaminants which turn out to be themselves agonists or antagonists for steroids will i nterfere with the evaluation. Thus, a substantial improvement in current screening techniques for agonists and antagonists would be effected by the availability of the purified human receptor protein.
In addition, because the availability of materials for recombinant production of a protein permits s eque nce modification, for example, by
site-specific mutagenesis, modification of characteristics of the product receptor, such as its ligand binding specificity is possible. Therefore the recombinant vectors of the invention provide the starting materials to obtain a series of modified receptors for a spectrum of processing conversions.
Finally, the recombinant receptor of the invention is also useful in providing a specific and sensitive diagnostic assay fur human receptor protein in biological samples. Such assays are important in, for example, diagnosis of tumor sensitivity to steroid metabolism. The availability of purified recombinant human receptor will provide this material for standardization and calibration of direct immunoassay.
D. Examples
Illustrated below is the construction of an expression system effective in producing recombinant human estrogen receptor. The examples are not to be construed as limiting the invention.
Example 1 Characterization of cDNA Encoding Human Estrogen Receptor 0R8 cDNA, obtained as described by Walter, P., et al, (supra), was subcloned into the EcoRI site of M13mp9 and clones containing both orientations of cDNA wore isolated and sequenced by the method of Sanger, F., et al, Proc Natl Acad Sci (USA) (1977) 74:5463; Schreirer, P.H., et al, J Mol Biol (1979) 121:169. The sequence obtained is shown in Figure 1. The open reading frame containing 1785 nucleotides corresponds to 595 amino acids and a calculated Mr of 66,200. Peptide sequences from purified hER are found throughout the
open reading frame and the location of the ATG start codon was surmised because, it is the first to appear downstream from the in frame terminator TGA at nucleotides -54 to -52. Comparison of the deduced amino acid sequence with the known sequences of human glucocortocoid receptor (GR) and to the product of the v-erb-A (AEU) oncogene showed strong homology in a region rich in cysteine, lysine and arginine, about 300-350 amino acids from the carboxy terminus of each. Extensiυe homologies are found in various corresponding regions of these proteins as shown in Figure 2.
Example 2 Construction of an Expression System The host expression vector contains the rnetallothionein-II promoter system (hMT-II) which is inducible in the presence of zinc ion, a viral enhancer, and about 600 bp of the 3' untranslated region of human growth hormone. The expression υector is obtained by replacing the human growth hormone encoding sequence from the vector designated phGHg-SU (10) which is constructed as described below. An alternate vector, also described, phGHg-SU(9) could also be used.
The construction of these vectors which are used as sources for the. host υector sequences is as follows:
The Promoter Sequences
The plasmid pHSl contains 840 bp of the hMT-II sequence from p84H (Karin, M., et al. Nature (1982) 299:297-302) which spans from the HindIII site at position -765 of the hMT-II gene to the BamHI cleavage site at base + 70. Plasmid p84H was digested to completion with BamHI, treated with exonuciease Bal-31
to remove terminal nucleotides, and then digested with Hindlll. The desired 840 bp Hindlll/blunt fragment was ligated into pUC8 (Uieira, J., et al, Gene (1982) 9:259-268) which had been opened with Hindlll and Hindi digestion. The ligation mixture was transformed into E. coli HB101 to Amp , and one candidate plasmid, designated pHS1, was isolated and sequenced by dideoxy sequencing. pHS1 contains the hMT-II control sequences upstream of a polylinker containing convenient restriction sites.
The hGH Sequence
Genomic sequences encoding hGH were isolated from p2.6-3 (DeNoto, et al, Nucleic Acids Res (1981) 19:3719)by digestion with BamHI, which cuts at the 5' end of the first exon, and EcoRI, which cuts 3' of the functional gene, followed by polyacrylamide gel purification. The isolated fragment was ligated into BamHI/EcoRI digested pHS1 and the ligation mixture transformed into E. coli MC1061 to AmpR. Successful transformants were, screened by restriction analysis, and a strain containing the desired plasmid, designated pMT-hGHg was further propagated to prepare quantities of plasmid DNA.
The Enhancer Sequence
A pair of host expression vectors containing the SV40 enhancer in operable linkage to the MT-II promoter and the 3' untranslated sequences from hGH was constructed by inserting an 1120 bp SU40 DNA fragment into the Hindlll site preceding the MT-II promoter sequences in pMT-bGHg. The SV40 DNA fragment spans the SV40 origin of replication and includes nucleotide 5171 through nucleotide 5243 (at the origin), the duplicated
72 bp repeat from nucleotide 107-250, and continues through nucleotide 1046 on the side of the origin containing the 5' end of late viral mRNAs. This Hindlll 1120 bp fragment is obtained from a Hindlll digest of SV40 DNA (Buchman, A.R., et al, DNA Tumor Viruses, 2d ed (J. Tooze, ed.), Cold Spring Harbor Laboratory, New York (1981), pp. 799-841), and cloned into pBR322 for amplification. The cloning vector was cut with Hindlll, and the 1100 bp SV40 DNA fragment isolated by gel electrophoresis and ligated into Hindlll-digested, CIP-treated, pMT-hGHg. The resulting vectors, designated phGHg-SV(9) and phGHg-SV (10), contain the fragment in opposite orientations preceding the MT-II promoter. In phGHg-SV(9), the enhancer is about 1600 bp from the 5' mRNA start site; in the opposite orientation it is approximately 980 bp from the 5' mRNA start site. Both orientations are operable, but the. orientation wherein the enhancer sequences are proximal to the start site, provides higher levels of expression. It is believed that deletions which place the enhancer 250-400 bp upstream of the. transcription start are optimal.
Insertion of hER cDNA phGHg-SV(10), prepared as above, was digested with BamHI and Smal to delete the hGH encoding sequences. (BamHI cleaves in the polylinker sequence; Srnal in the 3' untranslated region of hGH, leaving about 600 bp in the vector fragment.)
The vector fragment was blunted using Klenow and the 4 dNTPs and ligated with the blunted EcoRI 2.1 kb OR8 fragment described aboυe containing the estrogen receptor. The resulting υector, designated phER-SV(10) was cloned in E. coli, and then transformed into CHO-K1 cells and successful transformants isolated.
Example 3 Production of Recombinant hER Successful transformant colonies were grown in monolayer culture to confluency and a zinc-supplemented DMEM/Ham's F-12 medium (Ham, R.G., Proc Natl Acad Sci (USA) (1965) 53:288), released with EDTA, and homogenized by Polytron disruption in a buffer containing 10 mM Tris (pH 7.4) and 20 mM sodium molybdate. The homogenates were centrifuged at 250,000 x g for 30 min and the supernatant fractions were then labeled with 0.5 nM estradiol (57 Ci/mmol) with or without a 200 fold excess of non-radioactive control estradiol or diethylstilberterol for 60 min at 4°C. In a separate experiment, aliquots (200 μl) of labeled extract were incubated for 60 min at 4°C either in the presence or absence of rat monoclonal ER antibody (10 μg of D75P3γ, D547Sp or H222Spγ in a final υolume of 220 μl).
For sedimentation analyses, 200 μl aliquots of labeled extract or incubate were layered onto linear 10-30% sucrose gradients (3.5 ml ) prepared in 10 mM Tris, 10 mM sodium molybdate, 1.5 mM EDTA, pH 7.4 and either 10 rnM KCl (low salt) or 400 mM KCl (high salt) and centrifuged at 0°C for 15 hr at 253,000 x g. Successive 100 μl fractions were collected and radioactivity was measured in Triton X-100 toluene scintillation mixture at 35% counting efficiency.
C14-labeled ovalbumin (3.6 S) and C14-labeled IgG
(7.0 S) were used as sedimentation markers in parallel gradients.
Figure 3 shows the results of the sedimentation analyses. Panel A shows the profiles in low salt gradients of the extracts from hER transformed cells
(triangles) or extracts from untransformed cells
(circles) labeled with 0.5 nM estradiol. These results indicate the. presence of a labeled estradiol receptor complex which sediments at 8-9 S.
Panel B shows the corresponding profiles as obtained in high salt gradients. The estradiol labeled receptor protein from the transformed cells as shown (triangles) now has a sedimentation value, of 4 S. This verifies the production of ER as the formation of an 8-10 S salt sensitive hormone receptor complex in hypotonic extracts of responsive, cells is considered to be a diagnostic characteristic of steroid receptors.
Further verification is also shown in Figure. 3. When the hornogenates were labeled with 0.5 nM labeled estradiol/100 nM cold estradiol (closed circles) the estrogen receptor complex was abolished. Figure 3 also shows that the complex incubated with the anti-receptor antibody D75Pγ (open circles) shifts the sedimentation to an 8 S complex. In addition, the concentration of the estrogen receptor complex uias more than doubled by the inclusion of 10-4 M zinc ion in the culture medium 24 hr prior to cell harυest, consistent with the induction of the metallothionein promoter by zinc (data not shown). The foregoing sedimentation characteristics are entirely consistent with the expression of hER by the transformed cells.
Claims (12)
1. An expression system for vertebrate steroid receptor protein which comprises a DNA sequence encoding
SR operably linked to control sequences compatible with eucaryotic host cells
2. The expression system of claim 1 wherein the host cells are mammalian.
3. The expression system of claim 2 wherein the host cells are CHO cells.
4. The expression system of claim 1 wherein SR is estrogen receptor (ER).
5. The expression system of claim 4 wherein ER is human estrogen receptor (hER).
6. Recombinant host eucaryotic cells which contain the expression system of claim 1.
7. The host cells of claim 6 which are mammalian.
8 A method to produce recombinant vertebrate SR which comprises culturing the cells of claim 6 and recovering the SR protein.
9. The method of claim 8 wherein the SR is recovered by disrupting the cells, removing cell debris, and recovering clarified lysate.
10. Re combinant vertebrate steroid re ceptor produced by the method of claim 8.
11. The SR of claim 10 which is estrogen receptor.
12. The ER of claim 11 which is human ER.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83382986A | 1986-02-20 | 1986-02-20 | |
US833829 | 1986-02-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU7084787A true AU7084787A (en) | 1987-09-09 |
Family
ID=25265376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU70847/87A Abandoned AU7084787A (en) | 1986-02-20 | 1987-02-18 | Eucaryotic expression of steroid receptor proteins |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0258401A4 (en) |
JP (1) | JPS63502397A (en) |
AU (1) | AU7084787A (en) |
WO (1) | WO1987005049A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6307030B1 (en) | 1988-04-15 | 2001-10-23 | The University Of North Carolina At Chapel Hill | Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions |
FR2649994A1 (en) * | 1989-06-30 | 1991-01-25 | Aderegem | PROCESS FOR OBTAINING A WILD NATIVE WEST ESTROGEN RECEPTOR AND APPLICATIONS THEREOF |
CA2200423C (en) * | 1996-03-26 | 2006-12-19 | Sietse Mosselman | Novel estrogen receptor |
IT1313552B1 (en) * | 1999-06-29 | 2002-09-09 | European Molecular Biology Lab Embl | ISOFORMS OF THE HUMAN ESTROGEN ALPHA RECEPTOR |
CA2393045A1 (en) * | 1999-12-07 | 2001-06-14 | Sumitomo Chemical Co., Ltd. | Mutant er.alpha. and test systems for transactivation |
DE60228082D1 (en) * | 2001-05-31 | 2008-09-18 | Novartis Ag | NTEN AND NEW LIGANDS AND PHARMACEUTICAL COMPOSITIONS |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4232001A (en) * | 1978-09-22 | 1980-11-04 | University Patents, Inc. | Methods and materials for detection of estrophilin |
IL78314A0 (en) * | 1985-04-03 | 1986-07-31 | Biotechnology Res Ass | Expression vectors and methods for the production of recombinant human renin |
-
1987
- 1987-02-18 WO PCT/US1987/000341 patent/WO1987005049A1/en not_active Application Discontinuation
- 1987-02-18 AU AU70847/87A patent/AU7084787A/en not_active Abandoned
- 1987-02-18 JP JP50143587A patent/JPS63502397A/en active Pending
- 1987-02-18 EP EP19870901900 patent/EP0258401A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JPS63502397A (en) | 1988-09-14 |
EP0258401A4 (en) | 1989-06-13 |
EP0258401A1 (en) | 1988-03-09 |
WO1987005049A1 (en) | 1987-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2592063B2 (en) | Hybrid receptor for efficient determination of ligand, antagonist or agonist | |
US7129078B2 (en) | DNA encoding androgen receptor fragment | |
US6268221B1 (en) | Melanocyte stimulating hormone receptor and uses | |
EP0873405B1 (en) | Expression augmenting sequence elements (ease) for eukaryotic expression systems | |
Srinivasan et al. | Overexpression of full-length human glucocorticoid receptor in Spodoptera frugiperda cells using the baculovirus expression vector system | |
US5438126A (en) | Human thyroid hormone receptor DNA | |
JP2007529992A5 (en) | ||
US5614620A (en) | DNA binding proteins including androgen receptor | |
Cosgrove et al. | Purification and properties of insulin receptor ectodomain from large-scale mammalian cell culture | |
US5892018A (en) | DNA sequences encoding a brain sodium channel protein | |
AU7084787A (en) | Eucaryotic expression of steroid receptor proteins | |
JPH03504439A (en) | cDNA encoding the gamma subunit of the high affinity receptor for immunoglobulin E | |
CA1341305C (en) | Dna binding proteins including androgen receptor | |
WO1991007423A1 (en) | Dna binding proteins including androgen receptor | |
Hadlock et al. | T-antigen is not bound to the replication origin of the simian virus 40 late transcription complex | |
Marks et al. | Conservation of the DNA binding domain and other properties between porcine and rat glucocorticoid receptors | |
CN116199742A (en) | Preparation method of recombinant human chorionic gonadotrophin Fc fusion protein | |
WO1993004076A1 (en) | 141 transcription factor and methods of isolating same | |
JPH11155574A (en) | New protein belonging to mdc gene family and dna coding for the protein | |
CA2095635A1 (en) | Chinese hamster ovary cell retrovirus-like c particles | |
CN117327678A (en) | Mutant ribonuclease R and application thereof | |
JPH07242697A (en) | Telencephalon-specific membranous protein telencephalin and dna capable of coding the same | |
CN1984927A (en) | Compositions and methods of purifying myelin-associated glycoprotein (MAG) | |
JPH07165795A (en) | Human interleukin-2 receptor | |
JPH06197765A (en) | Cholescystokinin b/gastrin receptor |